media – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Jinghong Medical Secures Series A Strategic Financing, Co-led by Venture Capital and Binhu Industrial Group with FTEC Capital as Exclusive Financial Advisor

It was learned from Vcbeat on an exclusive basis that Jinghong Medical Technology Group, a flagship enterprise in the domestic medical sterilization and supply field, officially announced the successful completion of its Series A strategic financing recently. The financing round was jointly led by Wuxi Innovation Investment Group Co., Ltd. and Binhu Industrial Group, with follow-on investments from prestigious institutions such as Shanghai Digital Industry Group and Xiaoyar Capital. FTEC Capital acted as the sole financial advisor for this financing event. This milestone funding round not only embodies the capital market’s unwavering confidence in the medical sterilization and supply industry, but also indicates that Jinghong Medical has stepped into a new stage of accelerated development in its national chain deployment, technological upgrading and service scale expansion. Strong Rigid Demand in Sterilization & Supply Market, a Hundred-Billion-Yuan Sector According to the 2022-2028 Research and Development Prospect Report on China’s Third-party ...
- Source: drugdu
- 36
- December 29, 2025
Brazil to launch single-dose dengue vaccination program; Chinese companies help boost vaccine production capacity

“The public is very concerned and eagerly anticipating the fact that dengue fever, an epidemic that has plagued impoverished communities for decades, can finally be ‘solved with a single injection’,” Valesca Mión, health inspector of the Guarulhostra Quelidad community vaccination site in São Paulo state, told reporters on the 26th. She added that she had been notified that, with increased production capacity, the vaccination program would be expanded to cover the entire population. Brazil’s Ministry of Health recently announced that Brazil will begin single-dose dengue fever vaccination by the end of January 2026, with the first batch of 300,000 doses of dengue vaccine developed by the Butantan Institute already delivered. The Brazilian government has initially allocated 368 million reais, planning to provide a total of 3.9 million doses to the public healthcare system. The Butantan Institute is expected to deliver another 1 million doses by the end of January 2026. ...
- Source: drugdu
- 38
- December 29, 2025
China Biopharmaceutical’s innovative drug TQH3906 completes Phase II clinical trial.

On December 29, China Biopharmaceutical (01177) issued an announcement stating that the Group’s independently developed Class 1 innovative drug…TQH3906, a “TYK2/JAK1JH2 allosteric inhibitor,” has recently completed its Phase II clinical trial for moderate to severe plaque psoriasis. Results showed that all dose groups of TQH3906 demonstrated good safety and tolerability, and met the primary endpoint of the Phase II study. The study enrolled 209 patients, including a placebo group and five different TQH3906 dose groups, with oral administration once daily. In terms of efficacy, TQH3906 showed a good dose-response relationship. At the recommended phase 2 dose, after 12 weeks of treatment, the PASI75 response rate exceeded 90% and the PASI90 response rate exceeded 70%, which was significantly better than the PASI75 and PASI90 response rates in the placebo group (approximately 10% and 5%, respectively). In terms of safety, TQH3906 has a good overall safety profile, with the overall incidence of ...
- Source: drugdu
- 35
- December 29, 2025
Transcenta Group-B and EirGenix Reach Biopharmaceutical Manufacturing Collaboration Agreement

On December 29, Transcenta Holdings Group-B (06628) announced a strategic collaboration and non-exclusive technology licensing agreement with EirGenix. The agreement aims to advance integrated continuous flow manufacturing of biopharmaceuticals and improve global accessibility to affordable biopharmaceuticals. Under the agreement, the company will grant EirGenix a non-exclusive license to its highly integrated continuous flow bioprocess manufacturing (HiCB) platform and provide complete process documentation, core process technologies and experience, and regulatory support services. The company will receive a substantial upfront payment and milestone payments, and will be able to collect future royalties related to the commercialization of the licensed technology. This collaboration is expected to significantly reduce production costs, enabling patients worldwide to access high-quality, affordable biologics. EirGenix plans to use the HiCB platform for its biologics development programs and manufacturing operations, supporting CDMO customers seeking highly integrated continuous flow manufacturing solutions. https://finance.eastmoney.com/a/202512293604195792.html
- Source: drugdu
- 31
- December 29, 2025
Sinovac Biotech’s adsorbent tetanus vaccine officially launched

On December 26, 2025, the first batch of adsorbed tetanus vaccine developed and produced by Beijing Sinovac Biotech Co., Ltd., a subsidiary of Sinovac Biotech, was shipped, officially entering the market. The vaccine, which received registration approval from the National Medical Products Administration in August 2025, represents the culmination of more than four years of research and development efforts, marking a new domestically produced option for tetanus active immunization in my country. Tetanus is an acute toxic disease caused by Clostridium tetani, which enters through breaks in the skin or mucous membranes. Globally, there are approximately one million cases annually, with 300,000 to 500,000 deaths. Without medical intervention, the mortality rate is nearly 100%, and even with standardized treatment, the global mortality rate remains between 30% and 50%. In my country, the overall level of tetanus protection among the adult population is insufficient. Traditional passive immunization agents have limitations such ...
- Source: drugdu
- 31
- December 29, 2025
A blockbuster drug with a market value of 5 billion yuan has been approved for a new indication

Recently, Shenyang Sansheng Pharmaceutical announced that its core product, recombinant human thrombopoietin injection (Tebio), has been officially approved by the National Medical Products Administration for a new indication: for adult patients with chronic liver disease-related thrombocytopenia (CLDT) who are scheduled to undergo surgery (including diagnostic procedures) . It is worth mentioning that, according to data from PharmNet, TEBIA’s sales in domestic public medical institutions exceeded 5 billion yuan in 2024. This new indication is its fourth approved indication, which will further consolidate its leading position in the thrombocytopenia treatment market. 01 The Road to Glory The story of TBIA began in the early days of China’s biopharmaceutical industry. In 2005, when imported biopharmaceuticals dominated the Chinese market, 3SBio’s independently developed recombinant human thrombopoietin injection was approved for marketing, becoming the world’s only commercially available recombinant human thrombopoietin product and China’s first Class 1 new drug biological product approved in China. ...
- Source: drugdu
- 31
- December 29, 2025
2025 Biopharmaceutical CEO Star

In the biopharmaceutical industry in 2025, the names of several key figures were frequently mentioned. The choices they made during merger and acquisition negotiations, pipeline advancement, commercialization, or company turning points directly influenced the company’s trajectory that year. 01 CEOs who drive up the value of M&A deals In the unpredictable biopharmaceutical M&A landscape of 2025, one of the most memorable cases is the “value maximization” case involving Metsera . The obesity market was already hot due to GLP-1 competition, but Metera wasn’t a giant company. Its value stemmed more from the potential assessment of its early assets and its judgment of the future market landscape. The co-founders, Whit Bernard and Clive Meanwell , seized the opportunities presented by the times. Amidst a dazzling array of offers, they skillfully used their business negotiation techniques, controlling the pace, information disclosure, and bidding mechanisms to ultimately push Pfizer’s seemingly settled $7 billion ...
- Source: drugdu
- 31
- December 29, 2025
Hybio Pharmaceutical and Dr. Reddy’s Forge Strategic Cooperation on Peptide APIs to Advance Global Peptide Layout

Journalists have learned from Hybio Pharmaceutical (300199) that on December 25, a signing ceremony was held in Beijing between Hybio Pharmaceutical and the world-renowned pharmaceutical company Dr. Reddy’s Laboratories. The two parties formally signed a non-binding term sheet for strategic cooperation in the field of peptide Active Pharmaceutical Ingredients (APIs) and related formulations, marking a successful start to their strategic partnership. It is reported that this cooperation resulted from in-depth prior consultations and strategic alignment. In September 2025, the global CEO of Dr. Reddy’s led a team to visit Hybio’s headquarters and production bases. The two sides held deep discussions on key issues such as peptide drug R&D innovation, global commercialization strategies, and potential strategic directions, followed by multiple rounds of face-to-face exchanges during international conferences such as CPHI. According to the cooperation framework, the two parties have reached a preliminary consensus on the scope of cooperation and overall strategy ...
- Source: drugdu
- 32
- December 29, 2025
Phase II Clinical Trial Application for New Lung Cancer Intraoperative Visualization Drug FZ-P001 Sodium for Injection Has Been Accepted

China Securities Intelligent Finance News — On the evening of December 28, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (01349) announced that it has received an “Acceptance Notice” from the National Medical Products Administration (NMPA). The Phase II clinical trial application for its self-developed Class 1 innovative drug, FZ-P001 Sodium for Injection, has been accepted. The drug is intended for the intraoperative visualization of malignant lesions in patients with known or suspected lung cancer. According to the announcement, the drug is an innovative photosensitizer targeting folate receptor alpha (FRα). It utilizes near-infrared (NIR) fluorescence imaging technology to indicate residual tumor tissue and surgical margins during procedures, aiming to improve the surgical resection outcomes for solid tumors such as lung cancer. Citing relevant data, the announcement noted that in 2022, China saw 1.061 million new lung cancer cases and 733,000 deaths, with lung cancer ranking first in both incidence and mortality among malignant tumors. The ...
- Source: drugdu
- 30
- December 29, 2025
【EXPERT Q&A】What are the main testing standards for medical devices?

Drugdu.com expert’s response: The medical device testing standard system is extensive and meticulous, covering multiple dimensions such as physical properties, chemical properties, biocompatibility, electrical safety, environmental adaptability, software functionality, sterilization validation, and service life assessment. Below are some core aspects: I. Physical Property Testing Standards Testing Items: Dimensional accuracy, surface roughness, material hardness, pressure resistance, tensile strength, sealing performance, wear resistance, fatigue life, motion accuracy, positioning accuracy, etc. Relevant Standards: GB/T 16886.1, GB 9706.1, YY/T 0287, GB/T 14710, etc. II. Chemical Property Testing Standards Testing Items: Material composition, chemical stability, leachables/extractables, residual solvents, additive content, heavy metal content, etc. Relevant Standards: Specific standards involving material composition analysis, impurity and additive testing, migration testing, etc. III. Biocompatibility Testing Standards Testing Items: Cytotoxicity tests, skin sensitization tests, intracutaneous reactivity tests, acute systemic toxicity tests, blood compatibility tests, implantation tests, genotoxicity tests, subchronic toxicity tests, etc. Relevant Standards: ISO 10993 series standards (e.g., ...
- Source: drugdu
- 35
- December 29, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.